A Phase 1 interventional study of Digoxin and Nemtabrutinib in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of the study is to learn what happens to levels of digoxin in a healthy person's body over time. Researchers will compare what happens to digoxin in the body when it is given with and without another medicine called nemtabrutinib. Researchers are testing if digoxin levels in the body are different when digoxin is given with or without nemtabrutinib.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single oral dose of digoxin (Treatment A).
Drug: Digoxin
Participants receive a single oral dose of digoxin coadministered with a single oral dose of nemtabrutinib (Treatment B).
Drug: Digoxin · Drug: Nemtabrutinib
Oral administration
Oral administration
Also known as: MK-1026, ARQ 531
Area under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Digoxin
Blood samples will be collected to determine the AUC0-Inf of digoxin.
Time frame: At designated timepoints (up to approximately 7 days)
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Digoxin
Blood samples will be collected to determine the AUC0-Last of digoxin.
Time frame: At designated timepoints (up to approximately 7 days)
Maximum Plasma Concentration (Cmax) of Digoxin
Blood samples will be collected to determine the Cmax of digoxin.
Time frame: At designated timepoints (up to approximately 7 days)
Plasma Concentration 24 Hours Postdose (C24) of Digoxin
Blood samples will be collected to determine the C24 of digoxin.
Time frame: At designated timepoints (up to approximately 24 hours)
Time to Maximum Plasma Concentration (Tmax) of Digoxin
Blood samples will be collected to determine the Tmax of digoxin.
Time frame: Predose and at designated timepoints (up to approximately 7 days)
Apparent Terminal Half-life (t1/2) of Digoxin
Blood samples will be collected to determine t1/2 of digoxin.
Time frame: At designated timepoints (up to approximately 7 days)
Apparent Clearance (CL/F) of Digoxin
Blood samples will be collected to determine the CL/F of digoxin.
Time frame: At designated timepoints (up to approximately 7 days)
Apparent Volume of Distribution (Vz/F) of Digoxin
Blood samples will be collected to determine the Vz/F of digoxin.
Time frame: At designated timepoints (up to approximately 7 days)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 8 weeks
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.
Time frame: Up to approximately 8 weeks
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2023 to primary completion in Jan 2024, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Digoxin · ARQ531